Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses
Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.
Sponsor: Peking University Care Luzhong Hospital
A PHASE4 clinical study on Helicobacter Pylori Infection, this trial is completed. The trial is conducted by Peking University Care Luzhong Hospital and has accumulated 7 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE4
Status: Not Yet Recruiting → Completed
-
Feb 2023 — Apr 2024 [monthly]
Not Yet Recruiting PHASE4
-
Nov 2022 — Feb 2023 [monthly]
Not Yet Recruiting PHASE4
▶ Show 2 earlier versions
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE4
-
Jul 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE4
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Peking University Care Luzhong Hospital
- Shandong University
- Taierzhuang District People's Hospital
- Yuncheng Traditional Chinese Medicine Hospital
- Zhengzhou Central Hospital
- Zibo Central Hospital
For direct contact, visit the study record on ClinicalTrials.gov .